Teva Wins Patent-infringement Lawsuit Protecting Copaxone - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Teva Wins Patent-infringement Lawsuit Protecting Copaxone



The U.S. District Court for the Southern District of New York found in favor of Teva Pharmaceuticals in the company’s patent-infringement lawsuit against Momenta Pharmaceuticals/Sandoz and Mylan Laboratories/Natco Pharmaceuticals regarding Teva’s relapsing-remitting multiple sclerosis (RRMS) product, Copaxone, the company said in a June 23, 2012 press release.  The suit included infringement of multiple patents covering the chemical composition of Copaxone, methods of using the product, and processes for manufacturing the product.  The defendants had claimed that the patents were invalid and unenforceable, but the judge rejected this claim and ruled that the generic versions of Copaxone infringe upon Teva’s patents. This ruling should prevent FDA approval of generic versions in the US at least until the Orange Book patents expire on May 24, 2012. Teva believes the decision will further prevent the sale of generics until the process patent expires on September 1, 2015.

Mylan expressed its disappointment in the decision.  “While we have not yet had the opportunity to review the Court's opinion, we fully intend to evaluate our options for an appeal once the Court's full opinion becomes available,” stated Heather Bresch, CEO of Mylan, in a June 25, 2012 press release.   Mylan’s earnings guidance for 2012 and earnings targets for 2013 remain unchanged because they were not reliant on the launch of a generic Copaxone, Bresch added.  In 2008, Mylan had signed an agreement to license and supply India’s Natco Pharma’s glatiramer acetate prefilled syringes, a generic version of Copaxone.

Momenta, which had partnered with Sandoz, a division of Novartis, also stated its intention to appeal the decision. "We are disappointed that the court determined that Teva's patents were valid and infringed, and we look forward to reading the full opinion to understand its reasoning," commented Craig Wheeler, president and chief executive officer of Momenta in a June 22, 2012 press release.  "We remain confident in our legal position and we intend to appeal."

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race

Click here